CompletedPhase 2NCT00853580
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Kathryn North, MDUniversity of Sydney - Westmead
- Intervention
- Lovastatin ™(drug)
- Enrollment
- 146 enrolled
- Eligibility
- 8-15 years · All sexes
- Timeline
- 2009 – 2016
Study locations (12)
- The University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Chicago, Chicago, Illinois, United States
- NIH, Bethesda, Maryland, United States
- Children' Hospital Boston, Boston, Massachusetts, United States
- Washington University - St. Louis, St Louis, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Childrens Medical Center - Univ. of Texas SW Medical Center, Dallas, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Collaborators
Boston Children's Hospital · Children's Hospital of Philadelphia · Children's National Research Institute · Children's Hospital Medical Center, Cincinnati · National Cancer Institute (NCI) · University of Chicago · University of Utah · Washington University School of Medicine · Sydney Children's Hospitals Network · University of Texas Southwestern Medical Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00853580 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)